The emerging class of agents targeting factor XI/XIa offers the paradigm-shifting possibility of ‘haemostasis-sparing anticoagulation’: protection from stroke and other thromboembolic events with a benign bleeding profile. With three investigational agents now into late-phase development, two presentations delivered at the European Society of Cardiology (ESC) Congress 2024, one focusing on efficacy of the small molecule factor XIa inhibitor asundexian and one on safety of the monoclonal antibody factor XI inhibitor abelacimab, have added to our knowledge of this innovative and diverse class.
EMJ Cardiology 12 [Supplement 2] . 2024
October 2024
Latest articles
All articles
7 Mins
13th
March
Rare Anti-HMGCR-Induced Immune-Mediated Necrotising Myopathy
An acute necrotising myopathy is a distinct form of uncommon muscle disease characterised by the rapid advancement of weakness affecting…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
10 Mins
18th
December
Reducing the CV Risks of Smoking
Smoking is a major risk factor for cardiovascular disease (CVD) and responsible for around 25% of all CVD-related deaths worldwide…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.